Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. - Wikidata - awgldk - TriplyDB

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

http://www.wikidata.org/entity/Q38457067

about

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.New developments in the medical management of prostate cancer.Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells.Molecular genetics of prostate cancer: new prospects for old challenges Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways.Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to support a prognostic or diagnostic role?Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies.Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth.Dose dependent activation of retinoic acid-inducible gene-I promotes both proliferation and apoptosis signals in human head and neck squamous cell carcinoma.Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management.The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis.Castration-resistant prostate cancer: new science and therapeutic prospects.Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.Expression of cellular components in granulomatous inflammatory response in Piaractus mesopotamicus model.Prognostic value of activated Akt expression in oral squamous cell carcinoma.Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases CD24 expression is an independent prognostic marker in cholangiocarcinoma.Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation.AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation

P2860

Q24299235-31C07D48-D586-43D6-ACEF-97958536DB70 Q24680138-13597A9E-7850-43AF-9C24-190F18408010 Q24801685-BAD244B4-B3D6-4BE4-B11A-48693169D40A Q24810517-6012B270-9BF3-4573-BE16-7D53568836BF Q25257717-F024EF92-F9E1-461D-963E-5952D858257F Q27026839-A32319F4-E59F-4220-B716-CDB9E0D2DB54 Q28076745-F67A80F2-3B84-4A82-937C-28AEE0869A82 Q28382812-53DBFAA1-FB5E-456A-8828-513574CC4E34 Q28482249-D155562B-CDD9-4E33-9783-809B04EF2573 Q30438487-4296B288-7BC7-4761-BD25-24F0F09A07F2 Q30940949-4F9D4D0C-07AC-4247-81F9-CF43423B910A Q33566738-AA95CD40-B187-4F2A-A5EE-9F81E4AA912F Q33763973-1889074B-15D2-47D6-804D-863BAE23B9C0 Q33809489-9EB9273E-30E0-49B4-879B-D2DE24A40DE2 Q33977056-795251AF-9925-4902-9415-9DED5893C5A2 Q34074062-F1CA237A-2205-482D-9208-CF3F582E1309 Q34127462-DB30F501-81B0-41A3-8AC0-8983B7647B8C Q34141720-B17048E4-5803-4B05-B16A-A3DD394A306C Q34196216-C0488F5C-0DF7-437C-AEC7-2253B75FF6F9 Q34311399-4780CEC0-AFA3-4F1C-8340-34238542F8E4 Q34345248-3C9A3E97-172A-4B0F-BECC-0A52E6120A5A Q34410251-8F5FCE3C-852D-4649-8107-0BA13EE037CA Q34469245-B659394B-28AF-4114-A3F3-B606CDA564DD Q34516184-AB864074-D32F-455B-B2D4-A4163275CBC6 Q34525572-C4069548-F1A1-4C5F-9729-9ABF05AD2005 Q34543298-0377AD2E-60E2-4F34-9C0F-215E8EAD08E9 Q34618728-5A2B74EB-8FDD-4D87-A01B-B30CEE547559 Q34766747-2DD45E10-C057-491D-A499-394FED6371AE Q34771742-DD24137F-8596-4832-B17E-506AD63C5935 Q35069595-196DBA16-7D4C-4BA0-BCEA-6CF449207C33 Q35076264-00AF440C-ABB6-4252-8144-EDBED5D2B204 Q35080706-FDF4D15B-14AD-4EDC-B854-88154D6DB4E4 Q35161796-27405695-BFF6-4A64-9D22-4A3DF96CD4C5 Q35219430-FCDA5412-B77E-4A5E-AFA6-3CBEA9232C3B Q35588865-1249823B-D4A5-4CE6-9270-CAEDFC7F1569 Q35636781-2F0C3F39-2AEA-4363-A3AD-6DB652CE57D6 Q35749794-75D3773E-6034-4580-AB54-90CD81566156 Q35751592-097662FB-564E-4F28-A799-4C28404B9706 Q35791891-B3F7A2EC-0FEE-48C0-9169-819B326B749F Q35835242-944F9B9D-3E65-47F9-A865-7439C39AA163

P2860

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

http://www.wikidata.org/entity/Q38457067

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

@en

type

label

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

@en

prefLabel

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

@en

P1433

Q38457067-F3A49681-F73F-4FB7-8816-567850304DEB

P1476

Q38457067-9AE243EC-08FC-414A-A97D-DED7EEE86966

P2093

Q38457067-2D2CE462-B47A-4403-9B58-6FADEEE3BF2E

Q38457067-5FFCB87D-8904-4E7A-A90A-472AE428D43E

Q38457067-71BEDF71-4AD5-4360-A127-9C502E574B63

Q38457067-7A391CAA-998D-48A4-85CB-9251376BEE74

Q38457067-93768ED5-8244-4809-8DA2-E18DADEB7E91

Q38457067-B4387AC8-6DD4-4466-8C1F-27E3C2C7B471

Q38457067-E2692E8A-8720-4563-B0BD-8182B5455AA0

P304

Q38457067-BA35DC28-704F-42D0-9BDB-6EE71A39A90C

P31

Q38457067-802219C5-3272-442F-82BC-CF7A22F2E46B

P407

Q38457067-A825DE22-D710-4B8E-9542-959B24BF75D9

P433

Q38457067-78A72A34-416D-46CF-8B34-E73C188EA3A0

P478

Q38457067-CBC4D64F-37B2-4EF5-9D84-5CCE4314411E

P577

Q38457067-BECDB8EE-DEFE-4F5E-9BD3-3F18E8E52EF1

P698

Q38457067-11233E7E-65E0-41CA-A7A1-C19C81025A1E

P921

Q38457067-C302B32E-D115-42F7-B3D8-4FBFA3B5C4C3

P1433

Clinical Cancer Research

P1476

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

@en

P2093

Dean A Troyer

http://www.w3.org/2001/XMLSchema#string

Jeffrey I Kreisberg

http://www.w3.org/2001/XMLSchema#string

Michael Brattain

http://www.w3.org/2001/XMLSchema#string

Paramita M Ghosh

http://www.w3.org/2001/XMLSchema#string

Roble Bedolla

http://www.w3.org/2001/XMLSchema#string

Shazli N Malik

http://www.w3.org/2001/XMLSchema#string

Thomas Prihoda

http://www.w3.org/2001/XMLSchema#string

P304

1168-1171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11948129

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry